Albuminuria occurred in 15 and 11% of donors and non-donors, respectively (weighted hazard ratio, 1.46; 95% confidence ...

Researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham health care system, have found ...

In the trial SUSTAIN 6 (short for trial to evaluate cardiovascular and other long-term outcomes with semaglutide in subjects ...

(Journal of the American Heart Association) Living kidney donors did not have higher risks of hypertension and albuminuria in ...

Roughly 2.85 million patients with a qualifying hospital visit were identified with either clinical CKD or at risk for CKD.

Researchers from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, have found ...

A recent study in Nature Medicine shows semaglutide reduces kidney risks in non-diabetic obese patients with cardiovascular ...

A 28-year-old woman in Oregon became paralyzed from the waist down after a grand piano fell on her and severed her spinal ...

In addition to a 24% reduction in major kidney disease events, the semaglutide group had 18% less MACE at 3 years versus ...

Baseline patient characteristics were well-balanced, including kidney function and albuminuria status. The primary endpoint ...

In this cohort study of living kidney donors and nondonors with the same follow-up schedule, the risks of hypertension and albuminuria were not significantly different. After the initial drop in ...

Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has been shown in the SELECT Trial to be effective in ...